4568 On Other Exchanges
4568 is not on other exchanges.

daiichi sankyo co ltd (4568) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DAIICHI SANKYO CO LTD (4568)

Related News

No related news articles were found.

daiichi sankyo co ltd (4568) Related Businessweek News

No Related Businessweek News Found

daiichi sankyo co ltd (4568) Details

Daiichi Sankyo Company, Limited researches, develops, manufactures, imports, and markets pharmaceutical products worldwide. It offers drugs, such as prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone compilations; teneligliptin and pioglitazone type 2 diabetes mellitus inhibitors; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine and donepezil for treating Alzheimer’s disease; laninamivir for anti-influenza treatment; and silodosin for treating dysuria. The company also provides pharmaceutical drugs, including olmesartan and amlodipine antihypertensive agents; levofloxacin, a synthetic antibacterial agent; carvedilol for treating hypertension, angina pectoris, and chronic heart failure; pravastatin and atorvastatin antihyperlipidemic agents; iohexol to enhance visibility of diagnostic X-ray imaging; and loxoprofen, an anti-inflammatory analgesic. In addition, it offers naloxegol for opioid-induced constipation treatment; and colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus indication, as well as iron sucrose and ferric carboxymaltose injections for treating anemia. Further, it provides over the counter products, such as Lulu, a cold remedy; Daiichi Sankyo Ichoyaku, a digestive remedy; Loxonin S, an antipyretic analgesic; Patecs, an antiphlogistic analgesic for external use; and Transino for treating melisma. Additionally, the company offers ActHIB, a haemophilus influenzae type b vaccine; Rotarix, a rotavirus vaccine; Influenza HA Vaccine; and Live Attenuated Measles/Rubella Combined Vaccine. The company also manufactures and sells cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, intermediates, and pharmaceuticals and drugs for animals. It has research collaborations with Bristol-Myers Squibb, University of Texas MD Anderson Cancer Center, and Memorial Sloan Kettering Cancer Center. The company was founded in 1899 and is headquartered in Tokyo, Japan.

14,670 Employees
Last Reported Date: 06/19/17
Founded in 1899

daiichi sankyo co ltd (4568) Top Compensated Officers

Chairman & CEO
Total Annual Compensation: ¥126.0M
Compensation as of Fiscal Year 2017.
daiichi sankyo co ltd
Daiichi Sankyo Company, Limited Initiates Phase 2 Study of DS-8201 in Patients with HER2-Expressing Advanced Colorectal Cancer

Daiichi Sankyo Company, Limited announced that the first patient has been dosed in a global phase 2 study evaluating the safety and efficacy of DS-8201, an investigational HER2-targeting antibody drug conjugate (ADC), in patients with HER2-expressing advanced colorectal cancer who have received at least two prior lines of standard treatment. An increase in the number of approved targeted therapies for advanced colorectal cancer over the past decade has helped improve outcomes for some patients, however efficacy and tolerability of second and third-line treatments remain limited. Approximately 3% of colorectal cancers overexpress the HER2 protein, which is a well-established therapeutic target in breast and gastric cancer. In addition, research indicates that HER2 amplification may be associated with resistance to anti-epidermal growth factor receptor (EGFR)-targeted therapy and shorter survival. Currently, no approved HER2-targeting therapies exist for patients with colorectal cancer.

Daiichi Sankyo Company, Limited Presents at 4th Biologics & Biosimilars Congress Europe, Mar-05-2018 through Mar-06-2018

Daiichi Sankyo Company, Limited Presents at 4th Biologics & Biosimilars Congress Europe, Mar-05-2018 through Mar-06-2018. Venue: Maritim proArte Hotel Berlin, Friedrichstrasse 151, Berlin, Germany. Presentation Date & Speakers: Mar-06-2018, YUJI KASUYA, Director.

Daiichi Sankyo Company, Limited Presents at AsiaTIDES: Oligonucleotide and Peptide Therapeutics, Feb-27-2018 through Mar-01-2018

Daiichi Sankyo Company, Limited Presents at AsiaTIDES: Oligonucleotide and Peptide Therapeutics, Feb-27-2018 through Mar-01-2018. Venue: Westin Miyako Kyoto, Kyoto, Japan. Presentation Date & Speakers: Feb-27-2018, Junichi Koga, Head of R&D Division and Executive Officer, Osamu Sato, Executive Director, R&D Planning Department. Feb-28-2018, Osamu Sato, Executive Director, R&D Planning Department.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4568 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4568.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4568 Industry Range
Price/Earnings 67.1x
Price/Sales 2.6x
Price/Book 2.1x
Price/Cash Flow 71.6x
TEV/Sales 2.2x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact DAIICHI SANKYO CO LTD, please visit www.daiichisankyo.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.